|
1
|
Krzystyniak J, Ceppi L, Dizon DS and
Birrer MJ: Epithelial ovarian cancer: The molecular genetics of
epithelial ovarian cancer. Ann Oncol. 27 (Suppl 1):i4–i10.
2016.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Bogdanova N and Dörk T: Molecular genetics
of breast and ovarian cancer: Recent advances and clinical
implications. Balkan J Med Genet. 15 (Suppl):S75–S80.
2012.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Song H, Kwan SY, Izaguirre DI, Zu Z, Tsang
YT, Tung CS, King ER, Mok SC, Gershenson DM and Wong KK: PAX2
expression in ovarian cancer. Int J Mol Sci. 14:6090–6105.
2013.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Eccles MR, He S, Legge M, Kumar R, Fox J,
Zhou C, French M and Tsai RW: PAX genes in development and disease:
The role of PAX2 in urogenital tract development. Int J Dev Biol.
46:535–544. 2002.PubMed/NCBI
|
|
5
|
Terzić J, Muller C, Gajović S and
Saraga-Babić M: Expression of PAX2 gene during human development.
Int J Dev Biol. 42:701–707. 1998.PubMed/NCBI
|
|
6
|
Alwosaibai K, Abedini A, Al-Hujaily EM,
Tang Y, Garson K, Collins O and Vanderhyden BC: PAX2 maintains the
differentiation of mouse oviductal epithelium and inhibits the
transition to a stem cell-like state. Oncotarget. 8:76881–76897.
2017.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Narlis M, Grote D, Gaitan Y, Boualia SK
and Bouchard M: Pax2 and pax8 regulate branching morphogenesis and
nephron differentiation in the developing kidney. J Am Soc Nephrol.
18:1121–1129. 2007.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Mansouri A, Hallonet M and Gruss P: Pax
genes and their roles in cell differentiation and development. Curr
Opin Cell Biol. 8:851–857. 1996.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Feng Y, Tang Y, Mao Y, Liu Y, Yao D, Yang
L, Garson K, Vanderhyden BC and Wang Q: PAX2 promotes epithelial
ovarian cancer progression involving fatty acid metabolic
reprogramming. Int J Oncol. 56:697–708. 2020.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Piao Y, Liang J, Holmes L, Henry V, Sulman
E and de Groot JF: Acquired resistance to anti-VEGF therapy in
glioblastoma is associated with a mesenchymal transition. Clin
Cancer Res. 19:4392–4403. 2013.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Helfrich I, Scheffrahn I, Bartling S, Weis
J, von Felbert V, Middleton M, Kato M, Ergün S, Augustin HG and
Schadendorf D: Resistance to antiangiogenic therapy is directed by
vascular phenotype, vessel stabilization, and maturation in
malignant melanoma. J Exp Med. 207:491–503. 2010.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Folberg R, Hendrix MJ and Maniotis AJ:
Vasculogenic mimicry and tumor angiogenesis. Am J Pathol.
156:361–381. 2000.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Tang HS, Feng YJ and Yao LQ: Angiogenesis,
vasculogenesis, and vasculogenic mimicry in ovarian cancer. Int J
Gynecol Cancer. 19:605–610. 2009.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Maniotis AJ, Folberg R, Hess A, Seftor EA,
Gardner LM, Pe'er J, Trent JM, Meltzer PS and Hendrix MJ: Vascular
channel formation by human melanoma cells in vivo and in vitro:
vasculogenic mimicry. Am J Pathol. 155:739–752. 1999.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Racordon D, Valdivia A, Mingo G, Erices R,
Aravena R, Santoro F, Bravo ML, Ramirez C, Gonzalez P, Sandoval A,
et al: Structural and functional identification of vasculogenic
mimicry in vitro. Sci Rep. 7(6985)2017.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Valdivia A, Mingo G, Aldana V, Pinto MP,
Ramirez M, Retamal C, Gonzalez A, Nualart F, Corvalan AH and Owen
GI: Fact or fiction, it is time for a verdict on vasculogenic
mimicry? Front Oncol. 9(680)2019.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Itzhaki O, Greenberg E, Shalmon B, Kubi A,
Treves AJ, Shapira-Frommer R, Avivi C, Ortenberg R, Ben-Ami E,
Schachter J, et al: Nicotinamide inhibits vasculogenic mimicry, an
alternative vascularization pathway observed in highly aggressive
melanoma. PLoS One. 8(e57160)2013.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Dong X, Sun B, Zhao X, Liu Z, Gu Q, Zhang
D, Zhao N, Wang J and Chi J: Expression of relative-protein of
hypoxia-inducible factor-1α in vasculogenesis of mouse embryo. J
Biol Res (Thessalon). 21(4)2014.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Luo F, Yang K, Liu RL, Meng C, Dang RF and
Xu Y: Formation of vasculogenic mimicry in bone metastasis of
prostate cancer: Correlation with cell apoptosis and senescence
regulation pathways. Pathol Res Pract. 210:291–295. 2014.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Qiao L, Liang N, Zhang J, Xie J, Liu F, Xu
D, Yu X and Tian Y: Advanced research on vasculogenic mimicry in
cancer. J Cell Mol Med. 19:315–326. 2015.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Basu GD, Liang WS, Stephan DA, Wegener LT,
Conley CR, Pockaj BA and Mukherjee P: A novel role for
cyclooxygenase-2 in regulating vascular channel formation by human
breast cancer cells. Breast Cancer Res. 8(R69)2006.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Millimaggi D, Mari M, D'Ascenzo S, Giusti
I, Pavan A and Dolo V: Vasculogenic mimicry of human ovarian cancer
cells: Role of CD147. Int J Oncol. 35:1423–1428. 2009.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Sun J and Hemler ME: Regulation of MMP-1
and MMP-2 production through CD147/extracellular matrix
metalloproteinase inducer interactions. Cancer Res. 61:2276–2281.
2001.PubMed/NCBI
|
|
24
|
Sood AK, Fletcher MS, Coffin JE, Yang M,
Seftor EA, Gruman LM, Gershenson DM and Hendrix MJ: Functional role
of matrix metalloproteinases in ovarian tumor cell plasticity. Am J
Obstet Gynecol. 190:899–909. 2004.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Sood AK, Seftor EA, Fletcher MS, Gardner
LM, Heidger PM, Buller RE, Seftor RE and Hendrix MJ: Molecular
determinants of ovarian cancer plasticity. Am J Pathol.
158:1279–1288. 2001.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Labrie M, Vladoiu MC, Grosset AA, Gaboury
L and St-Pierre Y: Expression and functions of galectin-7 in
ovarian cancer. Oncotarget. 5:7705–7721. 2014.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Lin H, Pan JC, Zhang FM, Huang B, Chen X,
Zhuang JT, Wang H, Mo CQ, Wang DH and Qiu SP: Matrix
metalloproteinase-9 is required for vasculogenic mimicry by clear
cell renal carcinoma cells. Urol Oncol. 33:168.e9–e16.
2015.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Ayala-Domínguez L, Olmedo-Nieva L,
Muñoz-Bello JO, Contreras-Paredes A, Manzo-Merino J,
Martínez-Ramírez I and Lizano M: Mechanisms of vasculogenic mimicry
in ovarian cancer. Front Oncol. 9(998)2019.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Su M, Feng YJ, Yao LQ, Cheng MJ, Xu CJ,
Huang Y, Zhao YQ and Jiang H: Plasticity of ovarian cancer cell
SKOV3ip and vasculogenic mimicry in vivo. Int J Gynecol Cancer.
18:476–486. 2008.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Al-Hujaily EM, Tang Y, Yao DS, Carmona E,
Garson K and Vanderhyden BC: Divergent roles of PAX2 in the
etiology and progression of ovarian cancer. Cancer Prev Res
(Phila). 8:1163–1173. 2015.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Yao DS, Li L, Garson K and Vanderhyden BC:
The mouse ovarian surface epithelium cells (MOSE) transformation
induced by c-myc/K-ras in. Zhonghua Zhong Liu Za Zhi. 28:881–885.
2006.PubMed/NCBI(In Chinese).
|
|
32
|
Kutner RH, Zhang XY and Reiser J:
Production, concentration and titration of pseudotyped HIV-1-based
lentiviral vectors. Nat Protoc. 4:495–505. 2009.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Debnath J, Muthuswamy SK and Brugge JS:
Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini
grown in three-dimensional basement membrane cultures. Methods.
30:256–268. 2003.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Vigier S and Fülöp T: Exploring the
extracellular matrix to create biomaterials. In: Composition and
Function of the Extracellular Matrix in the Human Body [Internet].
Travascio F (ed). IntechOpen, Rijeka, 2016. https://doi.org/10.5772/62979.
|
|
35
|
Fonsato V, Buttiglieri S, Deregibus MC,
Puntorieri V, Bussolati B and Camussi G: Expression of Pax2 in
human renal tumor-derived endothelial cells sustains apoptosis
resistance and angiogenesis. Am J Pathol. 168:706–713.
2006.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Ponce ML: Tube formation: An in vitro
matrigel angiogenesis assay. Methods Mol Biol. 467:183–188.
2009.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Sivak JM, Mohan R, Rinehart WB, Xu PX,
Maas RL and Fini ME: Pax-6 expression and activity are induced in
the reepithelializing cornea and control activity of the
transcriptional promoter for matrix metalloproteinase gelatinase B.
Dev Biol. 222:41–54. 2000.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Marchenko GN, Marchenko ND and Strongin
AY: The structure and regulation of the human and mouse matrix
metalloproteinase-21 gene and protein. Biochem J. 372:503–515.
2003.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Mariya T, Hirohashi Y, Torigoe T, Tabuchi
Y, Asano T, Saijo H, Kuroda T, Yasuda K, Mizuuchi M, Saito T and
Sato N: Matrix metalloproteinase-10 regulates stemness of ovarian
cancer stem-like cells by activation of canonical Wnt signaling and
can be a target of chemotherapy-resistant ovarian cancer.
Oncotarget. 7:26806–26822. 2016.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Rodriguez JA, Orbe J, De Lizarrondo SM,
Calvayrac O, Rodriguez C, Martinez-Gonzalez J and Paramo JA:
Metalloproteinases and atherothrombosis: MMP-10 mediates vascular
remodeling promoted by inflammatory stimuli. Front Biosci.
13:2916–2921. 2008.PubMed/NCBI View
Article : Google Scholar
|
|
41
|
Christophorou NAD, Mende M, Lleras-Forero
L, Grocott T and Streit A: Pax2 coordinates epithelial
morphogenesis and cell fate in the inner ear. Dev Biol.
345:180–190. 2010.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Tong GX, Chiriboga L, Hamele-Bena D and
Borczuk AC: Expression of PAX2 in papillary serous carcinoma of the
ovary: Immunohistochemical evidence of fallopian tube or secondary
Müllerian system origin? Mod Pathol. 20:856–863. 2007.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Tung CS, Mok SC, Tsang YT, Zu Z, Song H,
Liu J, Deavers MT, Malpica A, Wolf JK, Lu KH, et al: PAX2
expression in low malignant potential ovarian tumors and low-grade
ovarian serous carcinomas. Mod Pathol. 22:1243–1250.
2009.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Wong KK, Izaguirre DI, Kwan SY, King ER,
Deavers MT, Sood AK, Mok SC and Gershenson DM: Poor survival with
wild-type TP53 ovarian cancer? Gynecol Oncol. 130:565–569.
2013.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Ueda T, Ito S, Shiraishi T, Kulkarni P,
Ueno A, Nakagawa H, Kimura Y, Hongo F, Kamoi K, Kawauchi A and Miki
T: Hyper-expression of PAX2 in human metastatic prostate tumors and
its role as a cancer promoter in an in vitro invasion model.
Prostate. 73:1403–1412. 2013.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Lee SB, Doberstein K, Baumgarten P,
Wieland A, Ungerer C, Bürger C, Hardt K, Boehncke WH, Pfeilschifter
J, Mihic-Probst D, et al: PAX2 regulates ADAM10 expression and
mediates anchorage-independent cell growth of melanoma cells. PLoS
One. 6(e22312)2011.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Hardy LR, Salvi A and Burdette JE:
UnPAXing the divergent roles of PAX2 and PAX8 in high-grade serous
ovarian cancer. Cancers (Basel). 10(262)2018.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Raffone A, Travaglino A, Saccone G,
Mascolo M, Insabato L, Mollo A, De Placido G and Zullo F: PAX2 in
endometrial carcinogenesis and in differential diagnosis of
endometrial hyperplasia: A systematic review and meta-analysis of
diagnostic accuracy. Acta Obstet Gynecol Scand. 98:287–299.
2019.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Gruss P and Walther C: Pax in development.
Cell. 69:719–722. 1992.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Luo Q, Wang J, Zhao W, Peng Z, Liu X, Li
B, Zhang H, Shan B, Zhang C and Duan C: Vasculogenic mimicry in
carcinogenesis and clinical applications. J Hematol Oncol. 13:1–15.
2020.PubMed/NCBI View Article : Google Scholar
|
